Cymbalta (duloxetine) Drug Overview 2019

Report
25 Pages
March 2019
Region: Global
Citeline
ID: 4846129

Drug Overview
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia in the US, and most recently, chronic musculoskeletal pain. The drug is also marketed for the treatment of women with moderate to severe stress urinary incontinence in Europe under the brand name Yentreve.

Cymbalta was formerly marketed by Boehringer Ingelheim in a number of European countries under the brand name Xeristar, although Eli Lilly has since reacquired exclusive rights to develop and market duloxetine. In Japan – where Cymbalta was not launched until April 2010 – the drug is jointly marketed by Shionogi and Eli Lilly for the treatment of depression and depressive symptoms.

OVERVIEW

Drug Overview
Product Profiles
Cymbalta: Depression
Cymbalta: Neuropathic pain

LIST OF FIGURES

Figure 1: The author's drug assessment summary of Cymbalta for depression
Figure 2: The author's drug assessment summary of Cymbalta for depression
Figure 3: Cymbalta sales for depression across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Cymbalta for neuropathic pain – SWOT analysis
Figure 5: The author's drug assessment summary of Cymbalta for neuropathic pain
Figure 6: The author's drug assessment summary of Cymbalta for neuropathic pain
Figure 7: Cymbalta sales for neuropathic pain disease across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES

Table 1: Cymbalta drug profile
Table 2: Approval history of Cymbalta for depression in the US, Japan, and five major EU markets
Table 3: Late-phase trials of Cymbalta for depression
Table 4: Cymbalta ongoing Phase III trials in depression
Table 5: Cymbalta for depression – SWOT analysis
Table 6: Cymbalta drug profile
Table 7: Cymbalta Phase III data in neuropathic pain syndromes
Table 8: Cymbalta sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26

Table of Contents

Related Topics

Related Reports

Major Depressive Disorder Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

Osteoarthritis - Market Insight, Epidemiology and Market Forecast - 2032

Peripheral Neuropathic Pain - Pipeline Insight, 2024

Neuropathic Pain Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

Neuropathic Pain Market By Drug class, By Indication, By Distribution channel: Global Opportunity Analysis and Industry Forecast, 2022-2032